Occupier

Find Out The Latest

Keep in touch with news and developments from The Oxford Science Park and its occupiers here.

You can also follow us on LinkedIn

Acquisition of ATDBio by Biotage AB to provide platform for further growth

20 Oct 2021

Acquisition of ATDBio by Biotage AB to provide platform for further growth Founders look forward to continued focus on customers and innovation Oxford and Southampton, UK, October 20 2021 – ATDBio, a leader in complex oligonucleotide synthesis, is pleased to announce that it has been acquired by the Swedish life sciences company Biotage AB1 for approximately £45m in cash and shares. The acquisition, which provides Biotage with expertise in... Read more

Exscientia Announces Pricing of $304.7m Upsized IPO & $160m Concurrent Private Placements

30 Sep 2021

OXFORD, England–(BUSINESS WIRE)– Exscientia plc (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, today announced the pricing of its upsized initial public offering in the United States of 13,850,000American Depositary Shares (“ADSs”) representing 13,850,000 ordinary shares at an initial public offering price of $22.00 per ADS,... Read more

DR. CAROLIN BARTH JOINS MIROBIO AS CEO TO LEAD PRECISION IMMUNOLOGY COMPANY FOCUSED ON CHECKPOINT AGONIST ANTIBODIES

21 Sep 2021

DR. CAROLIN BARTH JOINS MIROBIO AS CEO TO LEAD PRECISION IMMUNOLOGY COMPANY FOCUSED ON CHECKPOINT AGONIST ANTIBODIES Former Novartis executive to lead emerging biotech with a novel precision approach to autoimmune disease, supported by recent senior appointments MiroBio is exclusively focused on checkpoint agonists produced by its unique discovery engine that comprehensively maps inhibitory checkpoint signaling pathways Clinical initiation... Read more

Exscientia in $70M collaboration for anti-virals against coronavirus & other pandemic potential viruses

08 Sep 2021

Exscientia enters $70M collaboration to develop anti-viral therapeutics against Coronavirus and other viruses with pandemic potential Four-year agreement with Bill & Melinda Gates Foundation to discover and develop small molecule therapeutics with less susceptibility to variants and greater patient access than current approaches — Exscientia to use leading AI platform and in-house drug expertise to discover and develop five phase 1-ready... Read more

MHRA approval for Phase 1 trial of lead cancer vaccine OVM-200

10 Aug 2021

Regulatory approval of OVM-200 for Phase 1 signals a significant step for Oxford Vacmedix with the first clinical trial of a cancer vaccine based on the recombinant overlapping peptide platform Oxford 10th August 2021; Oxford Vacmedix, the UK-based biopharma company focused on the development of cancer vaccines announced today that approval for a Phase 1 trial of OVM-200 has been received from the MHRA (Medicines and Healthcare products... Read more

News